Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

NCT07419178 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria di Parma as lead sponsor.

NCT NCT07419178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07419178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Phase
Not applicable
Overall status
Recruiting
Start date
September 5, 2023
Completion date
April 30, 2027
Enrollment
265 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf)